Evaheart, founded in Houston, Texas, is dedicated to enhancing the quality of life for patients with advanced heart failure through innovative medical devices. Their core mission is to respect and maintain native heart pulsatility while providing effective mechanical support. The company's flagship product, the EVAHEART® Left Ventricular Assist Device (EVA2), features a hydraulically levitated "open vane" impeller and a novel double-cuff tipless inflow cannula, designed to support both short- and long-term patient needs. Evaheart primarily focuses on the medical device market, targeting healthcare providers and patients requiring advanced cardiac support.

Notable figures associated with Evaheart include leading cardiovascular surgeons and biomedical engineers who contribute to the development and refinement of their products. The company has attracted significant interest from investors in the medical technology sector, bolstering its research and development efforts. Evaheart's key achievements include successful clinical trials demonstrating the efficacy and safety of the EVA2 device, which has positively impacted patient outcomes by providing reliable and gentle blood circulation. Overall, Evaheart's innovations are making a substantial difference in the field of cardiac care, offering new hope to patients with severe heart conditions.